APA (7th ed.) Citation

M, S., ZW, M., T, B., H, T., Y, O., ET, L., . . . C, P. (2023). Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: The ARON-2 study. Cancer immunology, immunotherapy : CII, 72(9), 2961. https://doi.org/10.1007/s00262-023-03469-5

Chicago Style (17th ed.) Citation

M, Santoni, et al. "Real-world Effectiveness of Pembrolizumab as First-line Therapy for Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma: The ARON-2 Study." Cancer Immunology, Immunotherapy : CII 72, no. 9 (2023): 2961. https://doi.org/10.1007/s00262-023-03469-5.

MLA (9th ed.) Citation

M, Santoni, et al. "Real-world Effectiveness of Pembrolizumab as First-line Therapy for Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma: The ARON-2 Study." Cancer Immunology, Immunotherapy : CII, vol. 72, no. 9, 2023, p. 2961, https://doi.org/10.1007/s00262-023-03469-5.